Hims & Hers Health Bundle
Who controls Hims & Hers Health today?
The 2017-founded telehealth leader surged public in 2021 via SPAC, merging founder influence with venture and institutional stakes. By 2024–Q2 2025 it hit a $1.7 billion annualized revenue run-rate and 1.8–2.0 million subscribers, shifting ownership through dilution and secondary offerings.
Ownership mixes founder/insider holdings, top institutional investors, index funds and retail—shaped by SPAC-era dilution, option/RSU grants and recent secondary sales. See Hims & Hers Health Porter's Five Forces Analysis for strategic context.
Who Founded Hims & Hers Health?
Founders and early ownership of Hims & Hers trace to 2017, when Andrew Dudum, Jack Abraham, Hilary Coles and advisor Josh Elman launched a consumer‑health platform with concentrated founder and Atomic studio ownership and standard founder vesting.
Founding team composition
Co‑founders combined consumer tech, brand and product expertise to shape the company's direct‑to‑consumer telemedicine approach.
Initial ownership structure
Equity was concentrated with Dudum and Atomic’s studio vehicle; exact founding percentages were not publicly disclosed.
Vesting and protections
Founders followed customary 4‑year vesting with a 1‑year cliff and standard protective provisions and repurchase rights on unvested shares.
Seed investors
Early backers included Atomic, Thrive Capital, Forerunner, Redpoint, SV Angel and Founders Fund affiliates plus industry angels.
Pre‑SPAC financings
Series A/B/C rounds from 2018–2020 reportedly raised over $150,000,000 in aggregate at rising valuations.
Cap table dynamics
Founders and Atomic retained meaningful influence while allocating significant option pools to product, medical and growth hires to scale subscriptions.
Early stages showed no public founder disputes or cap‑table litigation; investor pro rata rights and conventional VC protections shaped subsequent ownership shifts.
Key ownership facts
This chapter highlights who founded Hims & Hers, early shareholder composition and structural terms that set the stage for later public ownership changes.
- Founders: Andrew Dudum, Jack Abraham, Hilary Coles; early advisor Josh Elman.
- Seed investors included Atomic, Thrive Capital, Forerunner, Redpoint, SV Angel and Founders Fund affiliates.
- Reported pre‑SPAC private financing exceeded $150,000,000 (2018–2020).
- Standard founder vesting (4 years, 1 year cliff) and repurchase rights applied; exact founding percentages were not publicly disclosed.
For context on mission and culture that influenced founder retention and early governance, see Mission, Vision & Core Values of Hims & Hers Health
Hims & Hers Health SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Hims & Hers Health’s Ownership Changed Over Time?
Key events reshaping Hims & Hers ownership include the January 2021 SPAC business combination with Oaktree Acquisition Corp. at an implied enterprise value near $1.6 billion, subsequent public float and PIPE placements that diluted pre-merger holders, rising institutional index and mutual-fund ownership through 2021–2023, and a 2024–2025 step-up in market value driven by strong revenue growth and GLP-1 expansion.
| Period | Ownership Change | Market/Financial Context |
|---|---|---|
| 2020–Jan 2021 | SPAC merger with Oaktree Acquisition Corp.; PIPE investors added; pre-merger holders diluted | Implied EV ~$1.6 billion; initial market cap ~$3–4 billion |
| 2021–2023 | Institutional ownership climbed (index funds, growth funds); insiders diluted percentage-wise | Institutional ownership >70% at points; major holders: Vanguard, BlackRock, Fidelity, Wellington, Morgan Stanley IM |
| 2024–1H 2025 | Investor base broadened; passive ownership sizable; insider beneficial ownership mid-to-high single digits | FY2024 revenue ~$1.47 billion (+~48%); market cap roughly $5–8+ billion into 1H 2025 |
Institutional passive holders (notably Vanguard and BlackRock) commonly accounted for a combined 15–20%+ of shares outstanding in 2024–2025 filings; CEO Andrew Dudum remained a top individual shareholder but with a beneficial stake in the low- to mid-single digits after SPAC dilution and later grants. There is no dual-class share structure; governance and board practices shifted toward large-cap investor expectations, emphasizing profitable growth, cash generation, and category expansion.
Ownership Snapshot and Strategic Effects
Ownership moved from concentrated pre-SPAC founders and early backers to a diversified mix of institutions, retail, and insiders, shaping strategy toward profitability and TAM expansion.
- SPAC merger (Jan 2021) introduced PIPE and public float, diluting early holders
- Institutional investors (Vanguard, BlackRock, Fidelity) became dominant shareholders by 2023
- FY2024 growth and GLP-1 opportunity boosted market cap and reinforced focus on cash generation
- Insider ownership aggregated mid-to-high single digits; CEO Dudum retained a leading individual stake
Further reading on company strategy and brand positioning is available in Marketing Strategy of Hims & Hers Health
Hims & Hers Health PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Hims & Hers Health’s Board?
As of mid-2025 the board of directors of Hims & Hers Health centers on CEO and co-founder Andrew Dudum alongside directors with healthcare, consumer, marketplace and finance experience; the board has trended toward greater independence since listing and includes former digital health and e-commerce executives plus investor representatives in observer or past director roles.
| Director | Role / Background | Independent |
|---|---|---|
| Andrew Dudum | CEO, Co-founder — consumer health, marketplace strategy | No |
| Independent Director A | Digital health executive, clinical product and operations | Yes |
| Independent Director B | E-commerce and direct-to-consumer leadership | Yes |
| Independent Director C | Finance and public company governance, audit committee | Yes |
| Investor Representative (historical/observer) | Venture / early investor background, occasional observer roles | Varies |
Voting structure is one-share-one-vote common stock with no dual-class, super-voting founder shares or golden share; control depends on coalitions of institutional holders and insiders rather than a single controller, and proxy votes in 2024–2025 showed typical large-cap support for director elections, auditor ratification and say-on-pay proposals.
Board and Voting Highlights
Key facts on board composition and shareholder voting as of 2024–2025.
- Board led by CEO Andrew Dudum with independent directors from digital health, e-commerce and finance
- One-share-one-vote common stock; no dual-class or super-voting structure
- Institutional investors and insider holdings determine outcomes; no controlling shareholder reported
- Executive comp and equity plan adjustments made following investor engagement and proxy feedback
For deeper context on company strategy and revenue that informs board oversight see Revenue Streams & Business Model of Hims & Hers Health; institutional ownership remained concentrated among mutual funds and ETFs in 2025 with top 10 holders typically owning a combined 20–35% of float according to public filings, and insider ownership (executives + directors) commonly cited in SEC reports around 5–12%.
Hims & Hers Health Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Hims & Hers Health’s Ownership Landscape?
Ownership of Hims & Hers has trended toward greater institutional and passive exposure through 2024–2025, with Vanguard and BlackRock among the largest passive holders while insider stakes have diluted to mid- to high-single digits amid secondary sales and equity grants.
| Holder Category | Representative Holders |
|---|---|
| Top institutional/passive | Vanguard, BlackRock, State Street — combined passive stakes expanded after index inclusions in 2024–2025 |
| Insiders | Founder/CEO Andrew Dudum and executive team — aggregate ownership in the mid- to high-single digits; periodic 10b5-1 sales and option exercises noted |
| Retail & growth funds | Retail float increased as stock rallied; thematic healthcare and growth funds entered following GLP-1, dermatology, and mental health launches |
Capital posture remained conservative: strong cash balances and focus on organic growth, with no leveraged buyout, take-private attempt, dual-class conversion, or recapitalization announced through 2024–2025; secondary liquidity from early holders occurred via market sales.
Passive ownership concentration
Index inclusion in 2024–2025 raised passive stakes, concentrating voting influence among a few asset managers while broadening retail float as the share price rallied.
Insider dilution and retention
Founder Andrew Dudum remains the largest insider, but percentage ownership fell to mid- to high-single digits after option exercises, 10b5-1 sales, and refreshed equity awards for retention.
Strategic expansion driving ownership shifts
2024–2025 launches in weight management (including GLP-1 pathways), dermatology, and mental health subscriptions attracted thematic healthcare investors, modestly reshaping quarterly top-holder lists.
Management guidance and market outlook
Management emphasized sustainable profitability, disciplined CAC, and organic category expansion rather than transformative M&A; no signs of privatization and potential inclusion in higher-tier indices could further shift ownership to passive funds.
For supplemental context on customer and market targeting that influenced investor interest, see Target Market of Hims & Hers Health
Hims & Hers Health Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Hims & Hers Health Company?
- What is Competitive Landscape of Hims & Hers Health Company?
- What is Growth Strategy and Future Prospects of Hims & Hers Health Company?
- How Does Hims & Hers Health Company Work?
- What is Sales and Marketing Strategy of Hims & Hers Health Company?
- What are Mission Vision & Core Values of Hims & Hers Health Company?
- What is Customer Demographics and Target Market of Hims & Hers Health Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.